Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/53000
DC FieldValueLanguage
dc.contributor.authorRodriguez-Perez, Jose C.
dc.contributor.authorGarcia-Bello, Miguel A.
dc.contributor.authorAnabitarte-Prieto, Aranzazu
dc.contributor.authorCompanioni, Osmel
dc.contributor.authorNovoa-Mogollon, Francisco J.
dc.contributor.authorSuarez-Ortega, Saturnino
dc.contributor.authorPlaza-Toledano, Celia
dc.contributor.authorRodriguez-Esparragon, Francisco
dc.contributor.otherRodriguez-Perez, J.C.
dc.contributor.otherRodriguez-Esparragon, Francisco
dc.contributor.otherGarcia-Bello, Miguel-Angel
dc.date.accessioned2019-02-04T14:40:36Z-
dc.date.available2019-02-04T14:40:36Z-
dc.date.issued2011
dc.identifier.issn1064-1963
dc.identifier.urihttp://hdl.handle.net/10553/53000-
dc.description.abstractWe evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate. After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 +/- 52.4 mu g/min; p < 0.001), SBP (16.4 +/- 8.7 mmHg; p < 0.001) and DBP (17.7 +/- 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics.
dc.publisher1064-1963
dc.relation.ispartofClinical and Experimental Hypertension
dc.sourceClinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510
dc.subject.otherRandomized Controlled-Trial
dc.subject.otherBlood-Pressure
dc.subject.otherOvert Nephropathy
dc.subject.otherHigh-Risk
dc.subject.otherPrevention
dc.subject.otherGuidelines
dc.subject.otherValsartan
dc.subject.otherLosartan
dc.subject.otherEvents
dc.titleAnti-Albuminuric Effects of the Angiotensin AT1 Receptor Blocker Telmisartan in Hypertensive Patients
dc.typeinfo:eu-repo/semantics/Article
dc.typeArticle
dc.identifier.doi10.3109/10641963.2011.561900
dc.identifier.scopus82455198894
dc.identifier.isi000297470200002
dcterms.isPartOfClinical And Experimental Hypertension
dcterms.sourceClinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510
dc.contributor.authorscopusid54412956400
dc.contributor.authorscopusid54412123900
dc.contributor.authorscopusid6506385286
dc.contributor.authorscopusid14061836500
dc.contributor.authorscopusid12786120600
dc.contributor.authorscopusid7003480889
dc.contributor.authorscopusid18034771800
dc.contributor.authorscopusid6603262370
dc.description.lastpage510
dc.identifier.issue8
dc.description.firstpage506
dc.relation.volume33
dc.type2Artículo
dc.identifier.wosWOS:000297470200002
dc.contributor.daisngid245684
dc.contributor.daisngid1700450
dc.contributor.daisngid10185782
dc.contributor.daisngid2952487
dc.contributor.daisngid4992898
dc.contributor.daisngid6018799
dc.contributor.daisngid9742321
dc.contributor.daisngid1305938
dc.identifier.investigatorRIDC-1247-2010
dc.identifier.investigatorRIDD-2810-2013
dc.identifier.investigatorRIDNo ID
dc.contributor.wosstandardWOS:Rodriguez-Perez, JC
dc.contributor.wosstandardWOS:Garcia-Bello, MA
dc.contributor.wosstandardWOS:Anabitarte-Prieto, A
dc.contributor.wosstandardWOS:Companioni, O
dc.contributor.wosstandardWOS:Novoa-Mogollon, FJ
dc.contributor.wosstandardWOS:Suarez-Ortega, S
dc.contributor.wosstandardWOS:Plaza-Toledano, C
dc.contributor.wosstandardWOS:Rodriguez-Esparragon, F
dc.date.coverdateDiciembre 2011
dc.identifier.ulpgces
dc.description.sjr0,403
dc.description.jcr1,074
dc.description.sjrqQ2
dc.description.jcrqQ4
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptGIR IUCES: Estrategia y Negocios Internacionales-
crisitem.author.deptIU de Cibernética, Empresa y Sociedad (IUCES)-
crisitem.author.deptDepartamento de Economía y Dirección de Empresas-
crisitem.author.deptGIR IUSA-ONEHEALTH 5: Reproducción Animal, Oncología y Anestesiología Comparadas-
crisitem.author.deptIU de Sanidad Animal y Seguridad Alimentaria-
crisitem.author.orcid0000-0003-0023-1063-
crisitem.author.orcid0000-0002-2540-5042-
crisitem.author.orcid0000-0003-1663-3673-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Cibernética, Empresa y Sociedad (IUCES)-
crisitem.author.parentorgIU de Sanidad Animal y Seguridad Alimentaria-
crisitem.author.fullNameRodríguez Pérez,José Carlos-
crisitem.author.fullNameSuárez Ortega, Sonia María-
crisitem.author.fullNameRodríguez Esparragón,Francisco Javier-
Appears in Collections:Artículos
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.